GLP-1 Medications for PMOS (formerly PCOS): Weight Loss, Fertility and What to Know in the UK

 Why Are Women With PMOS Asking About GLP-1 Medications? 

 GLP-1 receptor agonists, such as semaglutide and liraglutide, were initially developed to treat type 2 diabetes and support weight loss. Today, they are increasingly being discussed in relation to PMOS (polyendocrine metabolic ovarian syndrome), the updated term proposed by The Lancet for the condition previously known as PCOS.

Quick Answer: What is PMOS and why do GLP-1s matter for it?

Research suggests GLP-1 medications may help some women with PMOS improve:

• Weight management
• Insulin resistance
• Ovulation and fertility
• Metabolic health
• Inflammation
• Hormonal symptoms

Because PMOS is closely linked to metabolic dysfunction and insulin resistance, many clinicians and patients are exploring whether GLP-1 therapies could support broader symptom improvement beyond weight loss alone.

Why the Name Changed From PCOS to PMOS

Experts proposed renaming PCOS to PMOS because the condition affects far more than the ovaries. PMOS better reflects the complex hormonal, metabolic, and endocrine changes associated with the condition, including:

• Insulin resistance
• Weight gain
• Irregular periods
• Fertility challenges
• Increased cardiovascular risk
• Inflammation
• Mental wellbeing impacts

The new terminology highlights growing awareness that PMOS is a whole-body metabolic condition rather than purely a reproductive disorder.

Why Interest in GLP-1s Is Growing

Women across the UK are increasingly searching for information about how GLP-1 medications may affect:

• Fertility and ovulation
• Hormone balance
• Menstrual cycles
• Weight loss resistance
• Cravings and appetite regulation
• Mental wellbeing
• Long-term metabolic health

As clinical research expands, GLP-1 therapies are becoming part of wider conversations around personalised treatment options for women living with PMOS.

1. Metabolic and Hormonal Effects

Improvements in PCOS/PMOS and insulin resistance

These metabolic benefits may also reduce androgen levels and improve menstrual regularity -- promising findings for women struggling with PCOS/PMOS.

2.

Reproductive Health, Fertility, and Pregnancy: What Women With PMOS Should Know About GLP-1 Medications

GLP-1 medications such as Semaglutide and Tirezepitide are increasingly being discussed in relation to fertility, ovulation, and reproductive health in women with PMOS (formerly PCOS). Because PMOS is strongly linked to insulin resistance, hormonal imbalance, and metabolic dysfunction, researchers are exploring whether improving metabolic health may also improve reproductive outcomes.

Quick Answer: Can GLP-1 Medications Improve Fertility in PMOS?

Emerging evidence suggests GLP-1 medications may help restore ovulation and improve fertility in some women with PMOS, particularly those with insulin resistance or obesity-related metabolic dysfunction. However, these medications also carry important pregnancy and contraception considerations that women should understand before starting treatment.

Effects on Menstrual Cycles and Ovulation

Preclinical research suggests GLP-1 may influence reproductive hormone pathways involved in ovulation and metabolic regulation. Clinical evidence is still developing, but several studies have shown that weight loss and improved insulin sensitivity may help regulate menstrual cycles and support ovulation in some women with PMOS.

What the Evidence Shows About Ovulation Restoration

Research suggests that improving insulin resistance can positively affect ovulatory function in women with PMOS. Some studies involving GLP-1 receptor agonists have reported improvements in:

• Menstrual regularity
• Ovulation frequency
• Insulin sensitivity
• Metabolic markers associated with fertility

This is important because many women with PMOS experience irregular ovulation or anovulation linked to insulin resistance and hormonal imbalance.

Weight reduction associated with GLP-1 therapy may also improve fertility outcomes indirectly by lowering inflammation, improving metabolic health, and restoring hormonal signalling pathways involved in reproduction.

However, experts stress that GLP-1 medications are not currently considered standalone fertility treatments, and more long-term reproductive research is still needed.

Weight Loss, Fertility, and PMOS

Weight loss from GLP-1 medications may improve fertility for some women with PMOS, particularly when excess weight and metabolic dysfunction contribute to irregular cycles or ovulatory dysfunction.

Potential fertility-related benefits may include:

• Improved ovulation
• More regular periods
• Better insulin regulation
• Reduced inflammation
• Improved metabolic health before pregnancy

For some women, this may increase the likelihood of spontaneous conception.

Because fertility can improve unexpectedly during treatment, women who are not planning pregnancy should understand the importance of effective contraception while using GLP-1 medications.

Contraception and Pregnancy Warnings

Important: GLP-1 Medications May Affect Oral Contraceptives

Regulatory agencies such as the MHRA advise women using GLP-1 medications to use effective contraception because these drugs may reduce the absorption and effectiveness of oral contraceptive pills, particularly during periods of gastrointestinal side effects such as vomiting or diarrhoea.

What This Means Practically for Women

If you are taking a GLP-1 medication and do not want to become pregnant, it is important to discuss contraception options with your clinician. In some cases, healthcare professionals may recommend:

• Non-oral contraception methods
• Backup contraception during dose escalation
• Additional precautions if experiencing vomiting or severe digestive symptoms

This is particularly important because ovulation and fertility may improve during treatment, even in women who previously struggled with irregular cycles.

Pregnancy Considerations and Medical Planning

GLP-1 medications are generally not recommended during pregnancy, and women are usually advised to stop treatment before trying to conceive.

However, emerging pregnancy outcome data suggests that women discontinuing GLP-1 medications before pregnancy may face higher risks of:

• Excess gestational weight gain
• Gestational diabetes
• Preterm birth

This highlights the importance of careful pre-pregnancy planning and personalised medical support.

What to Discuss With a Clinician Before Trying to Conceive

Before starting or stopping GLP-1 medications, women with PMOS should discuss:

• Fertility goals and pregnancy timelines
• Ovulation changes during treatment
• Safe contraception options
• When to stop medication before conception
• Nutritional support during weight loss
• Metabolic health optimisation before pregnancy
• Risks of rapid weight regain after discontinuation

This type of planning can help reduce complications and support healthier pregnancy outcomes.

GLP-1 medications are changing conversations around PMOS, fertility, and metabolic health. Early evidence suggests these treatments may help some women restore ovulation, improve menstrual regularity, and support fertility through improved insulin sensitivity and weight management.

However, because fertility may improve unexpectedly, women should also understand the important contraception and pregnancy guidance associated with these medications.

As research continues to evolve, personalised medical advice remains essential for women considering GLP-1 therapies while planning pregnancy or managing reproductive health with PMOS.

3. Bone and Musculoskeletal Health

4. Mood and Mental Health

Some women report improved mood, but research is still evolving:

Supporting your body during weight loss treatment can make all the difference. From vitamins to collagen support, we've got you covered.

Ready to support your journey? Here's what we stock at TribElle.

Join the conversation

You don't have to go through this alone